Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1434-9949
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis ; volume:41 ; number:9 ; day:26 ; month:5 ; year:2022 ; pages:2755-2763 ; date:9.2022
Clinical rheumatology ; 41, Heft 9 (26.5.2022), 2755-2763, 9.2022

Creator
Pellicano, Chiara
Campagna, Roberta
Oliva, Alessandra
Leodori, Giorgia
Miglionico, Marzia
Colalillo, Amalia
Mezzaroma, Ivano
Mastroianni, Claudio Maria
Turriziani, Ombretta
Rosato, Edoardo
Contributor
SpringerLink (Online service)

DOI
10.1007/s10067-022-06219-7
URN
urn:nbn:de:101:1-2022120121073716384449
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Pellicano, Chiara
  • Campagna, Roberta
  • Oliva, Alessandra
  • Leodori, Giorgia
  • Miglionico, Marzia
  • Colalillo, Amalia
  • Mezzaroma, Ivano
  • Mastroianni, Claudio Maria
  • Turriziani, Ombretta
  • Rosato, Edoardo
  • SpringerLink (Online service)

Other Objects (12)

Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response

Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand

Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?

Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

Related objects